This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma | MicrobiomeTrials
← Back to trials NCT00081874
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma Completed PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2004-04Est. Completion: 2006-09
Enrollment target: 29 participantsLocations M.D. Anderson Cancer Center, Houston, Texas, United States Other microbiome trials you might be interested in Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax …
Birmingham, United States Est. completion Oct 1, 2028
Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination t…
Birmingham, United States Est. completion May 15, 2029
Background:
Most people with hairy cell leukemia have a BRAF gene mutation. They can be treated with BRAF inhibitors, d…
Bethesda, United States Est. completion Apr 30, 2028